Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    FT819

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Fate Pharma Shows FT819 CAR T-Cell Therapy Benefits In Lupus
    Fate Pharma Shows FT819 CAR T-Cell Therapy Benefits In Lupus

    26 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/26/3174247/24675/en/Fate-Therapeutics-Presents-New-Clinical-Data-at-ACR-Convergence-2025-Demonstrating-Immune-Remodeling-and-Durable-Responses-in-Patients-with-Systemic-Lupus-Erythematosus-Treated-wit.html

    GLOBENEWSWIRE
    26 Oct 2025
    Share Share
    Fate Therapeutics Receives RMAT Designation from FDA for FT819
    Fate Therapeutics Receives RMAT Designation from FDA for FT819

    14 Apr 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/04/14/3060843/24675/en/Fate-Therapeutics-Receives-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-from-FDA-for-FT819-to-Treat-Moderate-to-Severe-Systemic-Lupus-Erythematosus-SLE.html

    GLOBENEWSWIRE
    14 Apr 2025
    Share Share
    Fate Therapeutics First Lupus Patient In FT819 CAR-T Study
    Fate Therapeutics First Lupus Patient In FT819 CAR-T Study

    09 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/09/2878757/24675/en/Fate-Therapeutics-Announces-First-Lupus-Patient-Treated-in-Phase-1-Autoimmunity-Study-of-Off-the-shelf-FT819-CAR-T-cell-Program.html

    GLOBENEWSWIRE
    09 May 2024
    Share Share
    Fate's FT819 Autoimmune PoC Data At ASGCT Meeting
    Fate's FT819 Autoimmune PoC Data At ASGCT Meeting

    22 Apr 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/04/22/2867237/24675/en/Fate-Therapeutics-Announces-Presentation-of-FT819-Proof-of-Concept-Data-for-B-cell-mediated-Autoimmune-Diseases-at-ASGCT-Annual-Meeting.html

    GLOBENEWSWIRE
    22 Apr 2024
    Share Share